Charmacy Pharmaceutical Co., Ltd. (2289.HK)
HKD 9.0
(0.0%)
HKD 9.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -96.53 Million | 44.05 Million | -19.54 Million | 131.07 Million | 4.01 Million | 49.15 Million |
| Net Income | 51.34 Million | 90.38 Million | 23.15 Million | 40.55 Million | 40.15 Million | 45.43 Million |
| Depreciation & Amortization | 26.46 Million | 28.83 Million | 32.03 Million | 24.55 Million | 23.93 Million | 18.44 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -219.3 Million | -300.21 Million | 20.94 Million | -227.85 Million | -43.83 Million | 6.21 Million |
| Other non-cash items | 40.06 Million | 225.04 Million | -95.67 Million | 293.82 Million | -16.23 Million | -20.94 Million |
| Investing Cash Flow | 39.33 Million | 71.76 Million | -24.4 Million | -54.77 Million | -73.74 Million | -97.56 Million |
| Investments in PPE | -40.84 Million | -8.58 Million | -25.03 Million | -51.98 Million | -73.9 Million | -97.72 Million |
| Acquisitions | - | - | - | -2.85 Million | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 23.25 | - | 99.25 | - |
| Other Investing Activities | 80.18 Million | 80.35 Million | 637.63 Thousand | 58.28 Thousand | 159.69 Thousand | 157.07 Thousand |
| Financing Cash Flow | 101.26 Million | -191.21 Million | 74.4 Million | -2.67 Million | 54.12 Million | 29.16 Million |
| Debt repayment | -74.3 Million | -1.07 Billion | -824.1 Million | -888.62 Million | -578.35 Million | -671.3 Million |
| Dividends payments | -75.5 Million | -28.43 Million | -52.49 Million | -56.51 Million | -61.57 Million | -48.35 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 102.46 Million | 911.72 Million | 951 Million | 942.46 Million | 694.06 Million | 748.82 Million |
| Accounts receivables | -98.17 Million | -222.46 Million | -54.81 Million | -158.02 Million | -816.71 Thousand | 47.34 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -193.34 Million | -77.74 Million | 75.75 Million | -69.82 Million | -43.02 Million | -41.12 Million |
| Other working capital | 72.21 Million | - | - | - | - | - |
| Cash at beginning of period | 68.86 Million | 144.22 Million | 113.77 Million | 40.14 Million | 55.73 Million | 75.09 Million |
| Cash at end of period | 112.92 Million | 68.86 Million | 144.22 Million | 113.77 Million | 40.14 Million | 55.73 Million |
| Capital Expenditure | -40.84 Million | -8.58 Million | -25.03 Million | -51.98 Million | -73.9 Million | -97.72 Million |
| Effect of forex changes on cash | 5730.90 | 33.47 Thousand | - | 790.00 | 8606.00 | -100.53 Thousand |
| Net cash flow / Change in cash | 44.06 Million | -75.36 Million | 30.45 Million | 73.62 Million | -15.58 Million | -19.35 Million |
| Free Cash Flow | -137.38 Million | 35.46 Million | -44.58 Million | 79.09 Million | -69.88 Million | -48.57 Million |
| Breakdown | 2024 Q2 | 2023 FY | 2023 Q4 | 2023 Q2 | 2022 FY | 2022 Q4 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 26.74 Million | 51.34 Million | 24.99 Million | 26.35 Million | 90.38 Million | 69.83 Million |
| Depreciation & Amortization | 17.62 Million | 26.46 Million | 15.04 Million | 11.99 Million | 28.83 Million | 15.31 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -3.69 Billion | -219.3 Million | -187.18 Million | -104.34 Million | -300.21 Million | -9.35 Million |
| Other non-cash items | 3.47 Billion | 40.06 Million | 279.38 Million | -162.78 Million | 225.04 Million | -305.52 Thousand |
| Investing Cash Flow | -9.82 Million | 39.33 Million | -10.54 Million | 49.88 Million | 71.76 Million | 73.92 Million |
| Investments in PPE | -9.87 Million | -40.84 Million | -10.67 Million | -30.17 Million | -8.58 Million | -6.12 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 58.75 Thousand | 80.18 Million | 125.1 Thousand | 80.06 Million | 80.35 Million | 80.05 Million |
| Financing Cash Flow | 202.15 Million | 101.26 Million | -101.67 Million | 202.94 Million | -191.21 Million | -148.55 Million |
| Debt repayment | - | -74.3 Million | - | - | -1.07 Billion | - |
| Dividends payments | -14.92 Million | -75.5 Million | -63.52 Million | -11.97 Million | -28.43 Million | -13.75 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 217.08 Million | 102.46 Million | -38.15 Million | 214.91 Million | 911.72 Million | -134.8 Million |
| Accounts receivables | -3.67 Billion | -98.17 Million | -133.53 Million | 35.36 Million | -222.46 Million | 18.48 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -24.19 Million | -193.34 Million | -53.64 Million | -139.7 Million | -77.74 Million | -27.83 Million |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 112.92 Million | 68.86 Million | 92.91 Million | 68.86 Million | 144.22 Million | 72.85 Million |
| Cash at end of period | 130.58 Million | 112.92 Million | 92.91 Million | 92.91 Million | 68.86 Million | 73.73 Million |
| Capital Expenditure | -9.87 Million | -40.84 Million | -10.67 Million | -30.17 Million | -8.58 Million | -6.12 Million |
| Effect of forex changes on cash | 2856.00 | 5730.90 | -6972.00 | 12.7 Thousand | 33.47 Thousand | 16.86 Thousand |
| Net cash flow / Change in cash | 17.65 Million | 44.06 Million | - | 24.05 Million | -75.36 Million | 878.65 Thousand |
| Free Cash Flow | -184.56 Million | -137.38 Million | 121.57 Million | -258.95 Million | 35.46 Million | 69.36 Million |
LYEL
FORSE
600685
5935
MLB1
ITMZF